| abstract |
Described herein are methods for treating a metabolic disorder in an individual in need thereof, comprising co-administering to the individual a therapeutically effective amount of a modulating FXR and at least one second agent that is a CCR2 / CCR5 antagonist, ASK1 inhibitor, DPP-IV inhibitor, caspase protease inhibitor, SGLT2 inhibitor, acetyl-CoA carboxylase 8ACC inhibitor), diacylgricerol acyltransferase-1 inhibitor sodium bile acid cotransporter inhibitor, TLR-4 antagonist, PPAR alpha / delta agonist, or GLP-1 agonist, or a combination of these. |